Topi (Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 01)
Topiramate
Product Images NDC 53002-1547
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 53002-1547). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Topi (Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 02)
This appears to be a chart displaying cumulative rates for time to first seizure for two groups of individuals taking different dosages of topiramate. The x-axis (horizontal) represents time in days and the y-axis (vertical) represents the cumulative percentage of individuals who had not yet experienced a seizure. The two groups are distinguished by different colored lines and the number of individuals in each group is provided in parentheses next to the drug dosage.*
Figure 2: Reduction In 4-week Migraine Headache Frequency(studies 10 And 11 For Adults And Adolescents) (Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 03)
The text describes the change from baseline in the average monthly migraine period rate for the double-blind phase of a study involving Topamax at doses of 100 and 200 mg/day. There is a significant reduction in migraine period rate with Topamax, as demonstrated by a statistical analysis showing p-values of less than 0.001 and 0.0001.*
Label Image (Lbl530021547)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
